NASDAQ:FATE Fate Therapeutics Q3 2026 Earnings Date & Estimates $2.10 +0.06 (+2.70%) As of 09:47 AM Eastern This is a fair market value price provided by Massive. Learn more. Fate Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Fate Therapeutics in Q3 2026Fate Therapeutics is expected to post earnings of -$0.2701 per share on revenue of $1.14 million. In the same quarter a year earlier Fate Therapeutics reported -$0.27 per share on revenue of $1.74 million. Fate Therapeutics last reported on August 13, 2026, posting -$0.25 per share and beating the -$0.2536 consensus estimate. Fate Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2701Expected Revenue$1.14 millionPrior-Year EPS-$0.27Prior-Year Revenue$1.74 millionExpected Revenue Growth-34.6%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.25 (Beat by +$0.0036)Last Quarter Revenue$2.08 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Fate Therapeutics Q3 2026 Earnings FAQ When does Fate Therapeutics report Q3 2026 earnings? Fate Therapeutics (NASDAQ:FATE) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Fate Therapeutics' Q3 2026 earnings call? Fate Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Fate Therapeutics? Analysts expect Fate Therapeutics to post earnings of -$0.2701 per share for Q3 2026. How much revenue is Fate Therapeutics expected to report? The consensus revenue estimate for Fate Therapeutics is $1.14 million for Q3 2026. Fate Therapeutics Earnings HeadlinesFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)November 3 at 4:05 PM | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Average Target Price of $5.90November 3 at 2:45 AM | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 4 at 1:00 AM | Behind the Markets (Ad)Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Fate Therapeutics (FATE)October 28, 2026 | theglobeandmail.comFate Therapeutics, Inc. Presents Updated Preliminary Data For FT819 In Active Lupus Nephritis At American Society Of Nephrology Kidney Week 2026October 26, 2026 | marketscreener.comMFate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026October 26, 2026 | globenewswire.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses induced pluripotent stem cell (iPSC) technology to create standardized, potentially off-the-shelf immune cell products, including natural killer (NK) cells and T cells. Its research and development activities include iPSC-derived cell therapies engineered to recognize and attack cancer cells. Fate’s pipeline has included candidates such as FT819, an iPSC-derived, CD19-targeted CAR T-cell therapy, along with other investigational NK-cell and T-cell programs. These products are designed to provide consistent manufacturing, scalable production and potentially broader access than individualized cell therapies. Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts research and clinical development primarily in the United States while pursuing therapies intended for patients internationally. The company’s programs have been evaluated in clinical studies involving hematologic malignancies and other serious diseases. Scott Wolchko has served as the company’s president and chief executive officer.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageShopify's Small Q3 Miss Triggered a Big Sell-Off: What's Next?Are the Fears Around Alphabet’s Search Slowdown Warranted? Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
